Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Immunization of BALB/c Mice against Shigella sonnei Using a Multiepitope Protein Vaccine through Intranasal and Subcutaneous Administration.
Iran J Allergy Asthma Immunol
July 2024
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
As the most common cause of bacillary dysentery or shigellosis, Shigella sonnei (S nonnei) has spread throughout the world. Invasion of the colorectal epithelial cells by this facultative intracellular bacterium occurs via various virulence factors. The increase in the resistance rate highlights the need for novel interventions, particularly increasing the urgency of the development of Shigella vaccines that may offer an effective solution.
View Article and Find Full Text PDFImpact of an intranasal L-DBF vaccine on the gut microbiota in young and elderly mice.
Gut Microbes
November 2024
Bond Life Sciences Center, University of Missouri, Columbia, MO, USA.
Article Synopsis
- Bacillary dysentery, caused by Shigella spp., is a severe disease affecting low- and middle-income countries, especially impacting vulnerable groups like infants and the elderly through fecal-oral transmission.
- Researchers developed a promising vaccine, L-DBF, combining key proteins that showed broad protection in mouse models, particularly for high-risk groups.
- The study found that intranasal vaccination with L-DBF caused notable changes in the gut microbiota of young and elderly mice, suggesting vaccination can significantly influence gut health and the interaction between the immune system and gut bacteria.
Outer membrane protein C is a protective and unique vaccine antigen against Shigella flexneri 3a.
Sci Rep
October 2024
Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla Str. 12, 53-114, Wroclaw, Poland.
The anti-Shigella vaccine is one of the WHO's top priorities. Every year the disease kills more than 200,000 people worldwide and poses a serious threat to children under 5 years of age and the elderly. Increasing antibiotic resistance and limitations in diagnostics emphasize the need to develop an effective vaccine.
View Article and Find Full Text PDFEvaluation of the prophylactic effect of egg yolk antibody (IgY) produced against the recombinant protein containing IpaD, IpaB, StxB, and VirG proteins from Shigella.
Mol Immunol
September 2024
Department of Biology, Faculty of Basic Sciences, Imam Hossein University, Tehran, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction: Shigellosis is a gastrointestinal disease causes high morbidity and mortality worldwide, however, there is no anti-Shigella vaccine. The use of antibiotics in shigellosis treatment exacerbates antibiotic resistance. Antibodies, particularly egg yolk antibody (IgY), offer a promising approach to address this challenge.
View Article and Find Full Text PDFMIP vaccine in leprosy: A scoping review and future horizons.
Indian J Dermatol Venereol Leprol
August 2024
Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India.
Mycobacterium Indicus Pranii (MIP) vaccine is a killed vaccine developed in India for leprosy with immunotherapeutic as well as immunoprophylactic effects. MIP, earlier known as Mycobacterium welchii, is a rapidly growing non-pathogenic mycobacterium. The novelty of this bacterium is due to its translational application as an immunotherapeutic agent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!